Arterial Pressure and Stress-Dose Steroids in Cardiac Arrest.

• Status: Not yet recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Early stress-dose steroids are of uncertain efficacy in cardiac arrest. The current authors plan to conduct a pertinent mediation analysis using prospectively collected data from 2 prior randomized clinical trials of in-hospital cardiac arrest. These trials reported positive results on the vasopressin-steroids-epinephrine (VSE) combination. The current analysis is aimed at identifying mediators of the benefit associated with VSE, potentially attributable to its stress-dose steroid subcomponent. Tested mediators will include arterial pressure in the early postresuscitation period (primary), and arterial blood lactate in the early postresuscitation period and renal failure free days (secondary).

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Athens
• Collaborator: University of Thessaly
• Treatments: Arginine Vasopressin; Epinephrine; Epinephryl borate; Methylprednisolone; Racepinephrine; Vasopressins

Criteria

Inclusion Criteria:

Adult patients with vasopressor-requiring inhospital cardiac arrest according to guidelines for resuscitation 2005, defined as:

• epinephrine requirement for ventricular fibrillation/tachycardia

• or asystole, or

• pulseless electrical activity

Exclusion Criteria:

• Age < 18 years;

• Terminal illness or do-not resuscitate status;

• Cardiac arrest due to exsanguination;

• Cardiac arrest before hospital admission;

• Pre-arrest treatment with intravenous corticosteroids;

• Previous enrollment in or exclusion from the 2 studies included in the analysis.